Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

Genmab A/S Sponsored ADR (GMAB) closed the last trading session at $21.69, gaining 4.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 30.36 indicates a 40% upside potential.The average comprises seven short-term price targets ranging from a low of $20.00 to a high of$ 46.00, with a standard deviation of $8.82. While the lowest estimate indicates a decline of 7.8% from the curren ...